Pitfalls in detecting MET exon 14 skipping variants by DNA- and RNA-based next generation sequencing technologies in a large real-world cohort and results of the first multinational EQA schemes.
Clearer diagnostic guidelines for a lung cancer mutation help labs catch more patients eligible for targeted drugs, reducing missed treatment opportunities.
This J Mol Diagnostics study characterizes the technical failure modes in detecting MET exon 14 skipping — a clinically actionable NSCLC alteration targeted by capmatinib/tepotinib — across a large real-world cohort and the first multinational EQA scheme. Findings directly inform diagnostic protocol improvements and lab accreditation standards for a practice-ready treatment target.
What the study was
- Study design
- Large real-world cohort study + multinational external quality assessment (EQA)
- Population
- NSCLC patients with suspected MET exon 14 skipping alterations; multinational molecular diagnostic laboratories
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- The Journal of molecular diagnostics : JMD
Why it surfaced
Large real-world cohort + first multinational EQA for a fully-approved treatment target (MET ex14 in NSCLC). Technical pitfalls in a diagnostic context with direct treatment decisions make this immediately actionable for clinical molecular pathology labs. First EQA scheme = practice-standard setting.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.